Format

Send to

Choose Destination
Vaccine. 2013 Nov 22;31 Suppl 8:I46-52. doi: 10.1016/j.vaccine.2012.04.110.

Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel.

Author information

1
Medical Technology Assessment Sector, Ministry of Health, Ben Tbai 2, Jerusalem, Israel. Electronic address: jd.bailey@elsevier.com.

Abstract

Using World health Organization, CHOosing Interventions that are Cost Effective (WHO-CHOICE) methodology, cost-utility ratios were calculated for various interventions (Papanicolaou [Pap] smear, human papillomavirus [HPV]-DNA testing, visual inspection with acetic acid [VIA] and vaccination against HPV) at various frequencies to reduce the burden of cervical cancer and condyloma (in the case of the HPV vaccination) in Israel, which has a low prevalence of cervical cancer. All of the screening and/or vaccine interventions were very cost-effective. Attempts should be made to raise compliancy with Pap smears from the current opportunistic 12.1% per annum to screen everyone aged 20-64 once every 5 years in combination with HPV-DNA testing for persons aged 30-64 both before and/or after HPV vaccination is introduced. This article forms part of a regional report entitled "Comprehensive Control of HPV Infections and Related Diseases in Israel" Vaccine Volume 31, Supplement 8, 2013. Updates of the progress in the field are presented in a separate monograph entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.

KEYWORDS:

Cervical Cancer; Cost-Utility Analysis; HPV; Israel; Screening; Vaccination

PMID:
24229719
DOI:
10.1016/j.vaccine.2012.04.110
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center